1266676-71-4

Basic information

• Product Name: [4-(3,4-dimethoxyphenyl)-thiazol-2-yl]-isoquinolin-3-yl-amine
• Synonyms: [4-(3,4-dimethoxyphenyl)-thiazol-2-yl]-isoquinolin-3-yl-amine
• CAS NO: 1266676-71-4
• Molecular Weight: 363.44
• Mol File: 1266676-71-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: [4-(3,4-dimethoxyphenyl)-thiazol-2-yl]-isoquinolin-3-yl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: [4-(3,4-dimethoxyphenyl)-thiazol-2-yl]-isoquinolin-3-yl-amine(1266676-71-4)
• EPA Substance Registry System: [4-(3,4-dimethoxyphenyl)-thiazol-2-yl]-isoquinolin-3-yl-amine(1266676-71-4)

Safety Data

• Hazardous Substances Data: 1266676-71-4(Hazardous Substances Data)

Upstream product

• 927902-45-2 isoquinolin-3-yl-thiourea 
• 1835-02-5 2-Bromo-1-(3,4-dimethoxyphenyl)ethanone 
• 25475-67-6 isoquinolin-3-amine 

Downstream Products

• 1266676-98-5 N-[4-(3,4-dimethoxyphenyl)-thiazol-2-yl]-N-isoquinolin-3-yl-acetamide 
• 1266676-97-4 [4-(3,4-dimethoxyphenyl)-thiazol-2-yl]-isoquinolin-3-yl-methyl-amine 

Relevant articles and documents

COMPOUNDS AND METHODS FOR INDUCING BROWNING OF WHITE ADIPOSE TISSUE

The present invention provides a compound for inducing browning of white adipose tissue in vitro and in vivo of formula I, the preparation method thereof, as well as a composition comprising the same. Further, the present invention also relates to the use of the compound and the method to treat metabolic disorders, such as obesity and diabetes.

2-aminothiazoles as therapeutic leads for prion diseases

2-Aminothiazoles are a new class of small molecules with antiprion activity in prion-infected neuroblastoma cell lines (J. Virol. 2010, 84, 3408). We report here structure-activity studies undertaken to improve the potency and physiochemical properties of 2-aminothiazoles, with a particular emphasis on achieving and sustaining high drug concentrations in the brain. The results of this effort include the generation of informative structure-activity relationships (SAR) and the identification of lead compounds that are orally absorbed and achieve high brain concentrations in animals. The new aminothiazole analogue (5-methylpyridin-2-yl)-[4-(3-phenylisoxazol-5-yl)-thiazol-2-yl]-amine (27), for example, exhibited an EC50 of 0.94 μM in prion-infected neuroblastoma cells (ScN2a-cl3) and reached a concentration of ～25 μM in the brains of mice following three days of oral administration in a rodent liquid diet. The studies described herein suggest 2-aminothiazoles as promising new leads in the search for effective therapeutics for prion diseases.